The Technical Analyst
Select Language :
Kymera Therapeutics, Inc. [KYMR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Kymera Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Kymera Therapeutics, Inc. is listed at the  Exchange

0.07% $40.20

America/New_York / 28 mar 2024 @ 16:00


Kymera Therapeutics, Inc.: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 2 456.69 mill
EPS: -2.52
P/E: -15.95
Earnings Date: May 02, 2024
SharesOutstanding: 61.11 mill
Avg Daily Volume: 0.807 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Sell
Return On Asset: Neutral
DE: Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -15.95 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-2.71x
Company: PE -15.95 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-0.0274
(-100.07%) $-40.23
Date: 2024-03-29
Expected Trading Range (DAY)

$ 38.09 - 42.31

( +/- 5.24%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-14 Booth Bruce Sell 34 473 Common Stock
2024-03-14 Booth Bruce Sell 10 846 Common Stock
2024-03-14 Booth Bruce Sell 781 Common Stock
2024-03-15 Booth Bruce Sell 8 126 Common Stock
2024-03-15 Booth Bruce Sell 49 591 Common Stock
INSIDER POWER
46.08
Last 99 transactions
Buy: 3 034 623 | Sell: 1 008 904

Forecast: 16:00 - $40.16

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $40.16
Forecast 2: 16:00 - $40.16
Forecast 3: 16:00 - $40.16
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $40.20 (0.07% )
Volume 0.521 mill
Avg. Vol. 0.807 mill
% of Avg. Vol 64.60 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Kymera Therapeutics, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Kymera Therapeutics, Inc.

RSI

Intraday RSI14 chart for Kymera Therapeutics, Inc.

Last 10 Buy & Sell Signals For KYMR

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$33.94N/AActive
Profile picture for
            Kymera Therapeutics, Inc.

KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Last 10 Buy Signals

Date Signal @
WETHUSDMar 29 - 08:143 549.26
WMNTUSDMar 29 - 08:131.167
WLDUSDMar 29 - 08:148.27
RUNEUSDMar 29 - 08:15$9.05
PHBUSDMar 29 - 08:142.66
LDOUSDMar 29 - 08:142.88
ORAIUSDMar 29 - 08:1414.49
OKBUSDMar 29 - 08:14$63.74
FRAXUSDMar 29 - 08:14$0.994
ARKMUSDMar 29 - 08:142.64

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.